Efficacy ResultsCingulate recently reported positive efficacy results from its pediatrics study for CTx-1301, highlighting its potential in treating ADHD.
Market PotentialCingulate's focus on ADHD presents a large market potential, as ADHD affects millions of children, adolescents, and adults.
Technology AdvantageCingulate's Precision Timed Release (PTR) drug delivery platform offers a unique advantage by allowing once-daily, multi-dose tablets.